Remove Biopharma Remove Healthcare Remove Leads
article thumbnail

3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff

MedCity News

Healthcare M&A deals are expected to pick up over the next few months, and one expert is predicting that the biopharma sector in particular will see especially robust activity.

article thumbnail

The Direct-to-Patient Platform: Transforming the Patient Journey for Better Outcomes

Fierce Pharma

Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)

Patients 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Access solutions: the missing link that prevents biopharma innovation from reaching patients

pharmaphorum

However, most models are based on an old-fashioned and expensive call centre-based approach that fails to meet the needs of patients and healthcare providers (HCPs) as consumers. Yet, the healthcare experience is antiquated. entertainment or consumer apps), before it is production-worthy for mission-critical healthcare applications.

article thumbnail

Traversing the Biopharma Career Landscape

Pharmaceutical Commerce

In this latest Harvard Business School Healthcare Alumni Association Q&A, Dr. Peter Cappelli, Professor of Management at The Wharton School and Director of Wharton’s Center for Human Resources, explains how biopharma C-suites can lead their teams through 2023’s turbulent times.

article thumbnail

Leading innovators in transcription factors for AAV for the pharmaceutical industry

Pharmaceutical Technology

Encoded Therapeutics develops gene therapies for the treatment of severe genetic disorders.

article thumbnail

Global Biopharma Launches in the New World Order

PM360

Biopharma blockbusters in the last 10 years show a disturbing trend. As a top 10 biopharma company leader shared with us, “Real blockbusters are gone. Innovation Is Expanding, But Healthcare Systems Are Slow to Adapt. Driving scale in a slow-moving healthcare ecosystem is not just a challenge for cell and gene therapies.

article thumbnail

Developing an effective contamination control strategy

European Pharmaceutical Review

As part of The Future of Pharma/Biopharma Analysis 2023 , which took place on 28-29 June 2023, European Pharmaceutical Review ( EPR ) gathered an expert panel to discuss developing a modern contamination control strategy. Opening the session, moderator Tim Sandle highlighted six fundamental aspects of contamination control.